S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
A One Stop Shop for Everything Futures Trading (Ad)pixel
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
A One Stop Shop for Everything Futures Trading (Ad)pixel
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
A One Stop Shop for Everything Futures Trading (Ad)pixel
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
A One Stop Shop for Everything Futures Trading (Ad)pixel
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
NASDAQ:RARE

Ultragenyx Pharmaceutical - RARE Stock Forecast, Price & News

$41.41
+0.86 (+2.12%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$40.66
$43.00
50-Day Range
$39.96
$55.77
52-Week Range
$39.55
$89.72
Volume
902,961 shs
Average Volume
555,649 shs
Market Capitalization
$2.90 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$111.58

Ultragenyx Pharmaceutical MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
170.7% Upside
$112.09 Price Target
Short Interest
Bearish
4.80% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.28
Upright™ Environmental Score
News Sentiment
0.63mentions of Ultragenyx Pharmaceutical in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($8.45) to ($6.54) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.04 out of 5 stars

Medical Sector

579th out of 1,095 stocks

Pharmaceutical Preparations Industry

272nd out of 547 stocks

RARE stock logo

About Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

Receive RARE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

RARE Stock News Headlines

Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx to Participate at Citi BioPharma Conference
A family races the clock
Analyst Ratings for Ultragenyx Pharmaceutical
What 7 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical
What 6 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical
See More Headlines
Receive RARE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

RARE Company Calendar

Last Earnings
7/28/2022
Today
10/02/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RARE
Employees
1,119
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$112.09
High Stock Price Forecast
$142.00
Low Stock Price Forecast
$60.00
Forecasted Upside/Downside
+169.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
7 Analysts

Profitability

Net Income
$-454,020,000.00
Net Margins
-151.34%
Pretax Margin
-151.02%

Debt

Sales & Book Value

Annual Sales
$351.41 million
Book Value
$13.53 per share

Miscellaneous

Free Float
65,345,000
Market Cap
$2.90 billion
Optionable
Optionable
Beta
1.23

Key Executives

  • Dr. Emil D. Kakkis M.D. (Age 62)
    Ph.D., Founder, Pres, CEO & Director
    Comp: $1.28M
  • Ms. Mardi C. DierMs. Mardi C. Dier (Age 58)
    Exec. VP & CFO
    Comp: $812.24k
  • Mr. John Richard Pinion IIMr. John Richard Pinion II (Age 56)
    Chief Quality Operations Officer & Exec. VP of Translational Sciences
    Comp: $743.58k
  • Dr. Camille L. Bedrosian M.D.Dr. Camille L. Bedrosian M.D. (Age 69)
    Chief Medical Officer & Exec. VP
    Comp: $825.08k
  • Mr. Erik HarrisMr. Erik Harris (Age 52)
    Exec. VP & Chief Commercial Officer
    Comp: $797.57k
  • Mr. Theodore A. HuizengaMr. Theodore A. Huizenga (Age 51)
    Sr. VP, Corp. Controller & Principal Accounting Officer
  • Mr. Dennis Karl HuangMr. Dennis Karl Huang (Age 57)
    Chief Technical Operations Officer & Exec. VP
  • Ms. Danielle Keatley
    Sr. Director of Investor Relations & Corp. Communications
  • Ms. Karah Herdman Parschauer J.D.Ms. Karah Herdman Parschauer J.D. (Age 44)
    Chief Legal Officer & Exec. VP
  • Mr. Ernie W. Meyer (Age 58)
    Chief HR Officer & Exec. VP













RARE Stock - Frequently Asked Questions

Should I buy or sell Ultragenyx Pharmaceutical stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RARE shares.
View RARE analyst ratings
or view top-rated stocks.

What is Ultragenyx Pharmaceutical's stock price forecast for 2022?

7 brokers have issued twelve-month target prices for Ultragenyx Pharmaceutical's shares. Their RARE share price forecasts range from $60.00 to $142.00. On average, they expect the company's stock price to reach $112.09 in the next twelve months. This suggests a possible upside of 170.7% from the stock's current price.
View analysts price targets for RARE
or view top-rated stocks among Wall Street analysts.

How have RARE shares performed in 2022?

Ultragenyx Pharmaceutical's stock was trading at $84.09 at the beginning of the year. Since then, RARE shares have decreased by 50.8% and is now trading at $41.41.
View the best growth stocks for 2022 here
.

When is Ultragenyx Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our RARE earnings forecast
.

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) released its quarterly earnings results on Thursday, July, 28th. The biopharmaceutical company reported ($2.26) earnings per share for the quarter, missing analysts' consensus estimates of ($1.72) by $0.54. The biopharmaceutical company earned $89.34 million during the quarter, compared to analysts' expectations of $87.33 million. Ultragenyx Pharmaceutical had a negative trailing twelve-month return on equity of 60.76% and a negative net margin of 151.34%. The firm's quarterly revenue was up 2.7% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.45) earnings per share.

What is Emil D. Kakkis' approval rating as Ultragenyx Pharmaceutical's CEO?

41 employees have rated Ultragenyx Pharmaceutical Chief Executive Officer Emil D. Kakkis on Glassdoor.com. Emil D. Kakkis has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Ultragenyx Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), TG Therapeutics (TGTX), GW Pharmaceuticals (GWPH) and QUALCOMM (QCOM).

What is Ultragenyx Pharmaceutical's stock symbol?

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

How do I buy shares of Ultragenyx Pharmaceutical?

Shares of RARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ultragenyx Pharmaceutical's stock price today?

One share of RARE stock can currently be purchased for approximately $41.41.

How much money does Ultragenyx Pharmaceutical make?

Ultragenyx Pharmaceutical (NASDAQ:RARE) has a market capitalization of $2.90 billion and generates $351.41 million in revenue each year. The biopharmaceutical company earns $-454,020,000.00 in net income (profit) each year or ($7.32) on an earnings per share basis.

How many employees does Ultragenyx Pharmaceutical have?

The company employs 1,119 workers across the globe.

How can I contact Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The official website for the company is www.ultragenyx.com. The biopharmaceutical company can be reached via phone at (415) 483-8800, via email at ir@ultragenyx.com, or via fax at 415-483-8810.

This page (NASDAQ:RARE) was last updated on 10/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.